VTYX News and Press, Ventyx Biosciences Inc. From 12/20/22

Ventyx Biosciences ( NASDAQ: VTYX ) has filed for a $150M mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds to invest in a variety of interest-bearing instruments. ...

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage Phase 2 trials of VTX958 for psoriatic arthritis and Crohn’s disease are on track to initiate by year end ENCINITAS, Calif., ...

Ventyx Biosciences, Inc. (VTYX) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers ...

Ventyx Biosciences press release ( NASDAQ: VTYX ): Q3 GAAP EPS of -$0.59 misses by $0.15 . Cash, cash equivalents and marketable securities of $412.4 million as of September 30, 2022, including proceeds from recent private placement, are expected to fund operations int...

We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn’s disease and psoriatic arthritis this quarter Cash, cash equivalents and marketable securities of $412.4 million as of September 30, 2022, including proceeds from recen...

Summary Ventyx is a biotechnology company focused on treating auto-immune diseases. Ventyx went public in late 2021 and, in 2022, two events doubled VTYX stock price. Ventyx is a classic example of Third Point’s ability to be lifecycle investors throughout a company...

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, tod...

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, tod...

Summary Third Point LLC is an SEC-registered investment adviser based in New York. The firm was founded in 1995 by Daniel S. Loeb, who serves as Chief Executive Officer. Third Point focuses on event-driven, value-oriented investing. During the Third Quarter, Third Point returned -...

Summary Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu. As suc...